Glaxo cancer drug fails Phase 3

Glaxo (GSK +0.2%) and Genmab's Arzerra (ofatumumab) fails to meet its primary endpoint of a statistically significant improvement in progression-free survival (PFS) versus physicians' choice in patients with bulky fludarabine-refractory chronic lymphocytic leukemia (CLL). The median PFS for the ofatumumab cohort was 5.36 months compared to 3.61 months in the physicians' choice group. The companies sponsored the 122-patient Phase 3 study as a means to expand Arzerra's label in refractory CLL.

Genmab CEO Jan van de Winkel, Ph.D., says, "Although ofatumumab performed broadly in-line with previous data, today's result is disappointing. Based on this result, we do not anticipate applying for a label expansion for ofatumumab in this specific refractory CLL population."

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs